# Zipalertinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/zipalertinib

> The PDUFA target action date for zipalertinib, sponsored by Cullinan Therapeutics, Inc. (CGEM), is February 27, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the zipalertinib PDUFA date?

The PDUFA target action date for zipalertinib, sponsored by Cullinan Therapeutics, Inc. (CGEM), is February 27, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "An NDA for zipalertinib monotherapy for relapsed EGFR ex20ins NSCLC remains under review with a Prescription Drug User Fee Act target action date of February 27, 2027." Last confirmed November 10, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/zipalertinib)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-454408, https://www.sec.gov/Archives/edgar/data/1789972/000119312526454408/cgem-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/zipalertinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | zipalertinib |
| Codes | CLN-081 |
| Sponsor | Cullinan Therapeutics, Inc. (CGEM) https://sec-api.dev/companies/cgem/catalysts |
| Indications | active brain metastases |
| Modality | small_molecule |
| FDA designations | breakthrough |

## Timeline

### Nov 2022: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-02-27, last confirmed 2025-02-27.
- SEC Form 10-K (accession 0000950170-25-028346): "In November 2022, in collaboration with our partners at Taiho, we initiated the ongoing, pivotal Phase 2b portion of the REZILIENT1 clinical trial of zipalertinib 100 mg twice daily in adult NSCLC patients with EGFRex20ins mutations who progressed after prior systemic therapy." https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm

### Aug 2023: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-02-27, last confirmed 2025-02-27.
- SEC Form 10-K (accession 0000950170-25-028346): "In August 2023, our collaboration partners at Taiho initiated the ongoing global Phase 3 clinical trial testing zipalertinib plus standard-of-care chemotherapy versus standard-of-care chemotherapy alone in frontline adult NSCLC patients with EGFRex20ins mutations (REZILENT3)." https://www.sec.gov/Archives/edgar/data/1789972/000095017025028346/cgem-20241231.htm

### Oct 2025: interim data readout

- Status: scheduled. Date confidence: month. Indication: active brain metastases.
- First seen 2025-08-07, last confirmed 2025-08-07.
- SEC Form 10-Q (accession 0000950170-25-104551): "Taiho also plans to share initial data from the REZILIENT2 cohort exploring zipalertinib in patients with active brain metastases at the European Society for Medical Oncology Congress 2025 in October 2025." https://www.sec.gov/Archives/edgar/data/1789972/000095017025104551/cgem-20250630.htm

### Q1 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-02-27, last confirmed 2026-01-08.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-006998): "Zipalertinib rolling NDA submission expected to be complete in Q1 2026 and full enrollment of REZILIENT3 frontline study expected in H1 2026" https://www.sec.gov/Archives/edgar/data/1789972/000119312526006998/cgem-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-028343): "Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions" https://www.sec.gov/Archives/edgar/data/1789972/000095017025028343/cgem-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-268041): ""Additionally, following a positive pre-NDA meeting with the FDA in October, our partner Taiho plans to initiate a rolling submission of an NDA for zipalertinib in relapsed EGFR ex20ins NSCLC by year-end and expects to complete enrollment of the frontline study REZILIENT3 in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1789972/000119312525268041/cgem-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-268041): "Following a positive Type B pre-NDA meeting with the U.S. Food and Drug Administration in October, Taiho plans to initiate a rolling submission of an NDA in relapsed EGFR ex20ins NSCLC by the end of 2025." https://www.sec.gov/Archives/edgar/data/1789972/000119312525268041/cgem-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-028343): "Together with Taiho, we look forward to discussing next steps with the U.S. FDA and expect to submit an NDA in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1789972/000095017025028343/cgem-ex99_1.htm

### May 7, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-05-07, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210290): ""Further, with our partner Taiho, we announced FDA acceptance of our first NDA submission, representing a significant milestone for Cullinan Therapeutics and bringing zipalertinib meaningfully closer to being available for patients, with a PDUFA date of February 27, 2027." https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm

### late 2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-03-10, last confirmed 2026-05-07.
- SEC Form 10-Q (accession 0001193125-26-210304): "Taiho completed enrollment of the trial in February 2026 and expects to obtain top-line results by the end of 2026." https://www.sec.gov/Archives/edgar/data/1789972/000119312526210304/cgem-20260331.htm
- SEC Form 10-K (accession 0001193125-26-099362): "Taiho completed enrollment of the trial in February 2026 and expects to obtain top-line results by the end of 2026." https://www.sec.gov/Archives/edgar/data/1789972/000119312526099362/cgem-20251231.htm

### late 2026: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2026-10-02, last confirmed 2026-10-02.
- SEC Form 8-K (accession 0001193125-26-411011): "Completion of the Company's NDA submission is expected by year-end 2026." https://www.sec.gov/Archives/edgar/data/1789972/000119312526411011/cgem-20261001.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-411011): "After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission expected by year-end 2026" https://www.sec.gov/Archives/edgar/data/1789972/000119312526411011/cgem-ex99_1.htm

### February 27, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 2.
- First seen 2026-05-07, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-454408): "An NDA for zipalertinib monotherapy for relapsed EGFR ex20ins NSCLC remains under review with a Prescription Drug User Fee Act target action date of February 27, 2027." https://www.sec.gov/Archives/edgar/data/1789972/000119312526454408/cgem-ex99_1.htm
- SEC Form 8-K (accession 0001193125-26-411011): "An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act target action date of February 27, 2027." https://www.sec.gov/Archives/edgar/data/1789972/000119312526411011/cgem-20261001.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-411011): "An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027." https://www.sec.gov/Archives/edgar/data/1789972/000119312526411011/cgem-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210290): "Zipalertinib NDA for relapsed EGFR ex20ins NSCLC accepted by U.S. FDA; PDUFA target action date of February 27, 2027" https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210290): ""Further, with our partner Taiho, we announced FDA acceptance of our first NDA submission, representing a significant milestone for Cullinan Therapeutics and bringing zipalertinib meaningfully closer to being available for patients, with a PDUFA date of February 27, 2027." https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-454417): "Supported by data from the pivotal Phase 2b portion of the REZILIENT1 clinical trial, an NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under U.S. FDA review, with a Prescription Drug User Fee Act target action date of February 27, 2027." https://www.sec.gov/Archives/edgar/data/1789972/000119312526454417/cgem-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-336700): "The Prescription Drug User Fee Act (PDUFA) target action date is February 27, 2027." https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-210290): "The Prescription Drug User Fee Act (PDUFA) target action date is February 27, 2027." https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/cgem-ex99_1.htm

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/zipalertinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Zipalertinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/zipalertinib

```bibtex
@misc{secapidev_pdufa_zipalertinib_20261116,
  title        = {Zipalertinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/zipalertinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_zipalertinib_20261116","title":"Zipalertinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/zipalertinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
